EVEREST MED (ASX: 01952) has announced that it has entered into a definitive licensing agreement with Jixing Pharmaceutical Hong Kong Co., Ltd., a wholly-owned subsidiary of Jixing Pharmaceutical Co., Ltd. The agreement grants the company an exclusive license for the development, manufacturing, and commercialization of LNZ100 across the Greater China region, encompassing mainland China, Hong Kong, Macau, and Taiwan.

Under the terms of the deal, EVEREST MED will make an upfront payment, along with additional payments tied to achieving specific regulatory and sales milestones, plus tiered royalties based on future annual net sales. This transaction is anticipated to significantly expand the company's portfolio of innovative products, bolster its strategic presence in the ophthalmology sector, and enhance overall business synergies.

LNZ100 is a once-daily prescription eye drop designed for the treatment of presbyopia. Its active ingredient, aceclidine, is a small molecule muscarinic acetylcholine receptor agonist that induces pupil constriction, creating a pinhole effect to improve near vision. Research indicates that aceclidine has an ideal mechanism of action, producing the desired miotic effect while avoiding induced myopic shift.

The compound's unique, highly selective pupilary mechanism, which decouples pupil constriction from myopic shift, gives it the potential to address a broad patient population. LNZ100 received approval in the United States in July 2025 and was commercially launched there in October of the same year. In China, a New Drug Application (NDA) for LNZ100 was submitted in September 2025, with approval expected in the first quarter of 2027. This therapy holds significant potential to meet a large, unmet medical need in China, positioning itself as a best-in-class, non-invasive treatment option for presbyopia.